BALB/c mice were immunized with recombinant plasmid DNA pSVK3-ENS1 and pcDNAI-NS3 containing, respectively, genes E-NS1 and NS3 of tick-borne encephalitis (TBE) virus. Antibodies to TBE virus proteins were detected in the blood sera of the immunized animals by the method of the enzyme immunoassay. Though the titers of virus-specific antibodies in the sera of mice immunized with protein vaccines exceeded those registered after immunization with DNA vaccines, essential protective immunity was observed after the use of both vaccines.
The correction of radiation-induced immunodeficiency and hematopoiesis depression in clinical setting (100 patients) and in experiments (160 animals) by peptide preparations of the thymus and bone marrow (thymalin, hemalin, thymogemine and synthetic thymalin analog thymogen) has been studied. Administration of the bone marrow and thymus recovery of damage to the thymus, bone marrow, spleen and lymph nodes, improved the function of circulating neutrophilic granulocytes. Thymalin was able to compensate for immune disturbances and reduce manifestations of asthenia.
The aerodynamic properties of 99mTc radiolabeled carrier-free terbutaline sulphate (TBS) have been thoroughly investigated following delivery by Turbuhaler (AstraZeneca Lund, Sweden). A full and detailed radiolabeling procedure is also reported. The in vitro radiolabel validation was performed to determine whether TBS radiolabeled in this way would be representative of the commercially available product Bricanyl Turbuhaler during clinical trials. The results indicated that variations in aerodynamic properties had been introduced and that the radiolabel would slightly underestimate the fine particle fraction of Bricanyl, but would nonetheless act as a suitable marker in vivo. Assumptions regarding the aerodynamic properties of doses likely to be received by clinical trial subjects were also examined. This has been achieved by extending the validation procedures beyond those usually reported to include dose number, time, and homogeneity dependent studies. It was found that doses extracted for testing purposes and simulated patient doses extracted shortly afterward had similar properties. Doses extracted 2 h after initial testing also had similar properties to the test doses. These results suggested that data from the test doses could be used for quality control purposes, would be representative of the doses to be received by clinical trial subjects, and that a short delay between initial testing and trial subject inhalation would be acceptable.
Application employment of the proposed nitroglycerin ointment, original in its composition, permits the attacks of angina pectoris to be controlled, their onset to be prevented and adverse events associated with the use of nitrates to be eliminated. Therapeutic benefit becomes clinically apparent with small doses of nitroglycerin, the ointment itself is good for repeated therapeutic and prophylactic application.
Application of 1% of chloramphenicol (gel and cream) for local treatment of Pseudomonas aeruginosa burn infection has been studied in experiment. In vivo, both medical forms show pronounced therapeutic effect, they promote elimination of P. aeruginosa from wounds and decrease inflammation. In noninfected thermal trauma in laboratory animals application of gel and cream of chloramphenicol reduces transition from the phase of inflammation to the phase of reparation by 3-8 days and prevents infection of the burn wound by conditionally pathogenic microflora.
It was shown that the agonist of peripheral ORL1 receptors nociceptine raises heart resistance to the antiarrhythmic effect of aconitine. The antiarrhythmic effect of nociceptine is not connected with a change in the tonus of the autonomous nervous system or with an effect on opiate receptors. It is assumed that the antiarrhythmic properties of nociceptine are realized through inhibition of Na+/Ca2+ metabolism or blockade of rapid Na(+) channels of the cardiomyocytes.
Animal and human studies have suggested that antidepressant medications may be associated with several cancers. The authors evaluated the association between antidepressant medication use and the risk of non-Hodgkin's lymphoma using a Canadian population-based case-control study, the National Enhanced Cancer Surveillance Study. Non-Hodgkin's lymphoma cases (n=638) diagnosed in 1995-1996 were identified using the Ontario Cancer Registry, and controls (n=1,930) were identified from the Ontario Ministry of Finance Property Assessment Database. Antidepressant medication use was ascertained using a self-administered questionnaire. Multivariate logistic regression was used to estimate odds ratios. "Ever" use of antidepressant medications was not associated with non-Hodgkin's lymphoma risk. The odds ratio for non-Hodgkin's lymphoma with 25 or more months of tricyclic antidepressant medication use was 1.6; however, this was nonsignificant. Duration or history of use or individual types of antidepressant medications were not associated with non-Hodgkin's lymphoma risk. These findings do not support an increased risk of non-Hodgkin's lymphoma with antidepressant medication use.